Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 956Neoplasms 755Carcinoma, Non-Small-Cell Lung 742Prostatic Neoplasms 569Colorectal Neoplasms 499Lung Neoplasms 444Neoplasm Metastasis 400Multiple Myeloma 371Leukemia, Myeloid, Acute 351Ovarian Neoplasms 307Pancreatic Neoplasms 301Melanoma 273Squamous Cell Carcinoma of Head and Neck 257Recurrence 248Carcinoma, Hepatocellular 229Glioblastoma 223Brain Neoplasms 219Head and Neck Neoplasms 199Triple Negative Breast Neoplasms 198Carcinoma, Renal Cell 197Precursor Cell Lymphoblastic Leukemia-Lymphoma 190Lymphoma 188Stomach Neoplasms 186Endometrial Neoplasms 177Lymphoma, Non-Hodgkin 172Sarcoma 168Glioma 165Uterine Cervical Neoplasms 160Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 157

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Differentiated Thyroid Cancer (DTC) × 90 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡